Breast Cancer

Orion Genomics announces discovery, validation of novel breast cancer biomarkers

Published in Genetics and Environmental Business Week, January 18th, 2007

Orion Genomics has identified and validated a suite of novel breast cancer biomarkers, the most promising of which will be incorporated into the company's diagnostic assays for the early detection of breast cancer and the detection of breast cancer recurrence.

Using proprietary genome-wide microarray technology, the company was able to quickly identify a suite of novel biomarkers in a panel consisting of normal and cancerous breast tissues. In a second independent biomarker validation panel of more than 200 normal and cancerous breast tissues, over 50 biomarkers demonstrated significant diagnostic potential, the most promising of which presented 90% sensitivity and 96%...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Genetics and Environmental Business Week

Source: Genetics and Environmental Business Week (2007-01-18)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry